China bribery probes spread to first domestic firm and Alcon
This article was originally published in Scrip
The ever-spreading bribery investigations in China have now caught a major domestic manufacturer in their web. Chia Tai Tianqing (CTTQ) Pharmaceutical, a Chinese producer of liver drugs, was exposed on the country's state-run TV station CCTV earlier this month as having paid doctors – mostly from big hospitals in Jiangsu province – for frequent trips to Thailand and Taiwan to attend academic seminars.
You may also be interested in...
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.
The China Food and Drug Administration has released the final version of its biosimilars guideline1.